Table 3.
Symptom scores before and after prosima™ reconstructive pelvic floor surgery (n = 48)
| Variables | Preoperative | Postoperative | P |
|---|---|---|---|
| PGI-C, (n (%)) | |||
| 1 | − | 2 (4.2) | |
| 2 | - | 5 (10.4) | |
| 3 | - | 13 (27.1) | |
| 4 | - | 21 (43.8) | |
| 5 | - | 7 (14.6) | |
| PISQ-12 | |||
| Mean ± SD | 28.6 ± 6.2 | 32.3 ± 6.2 | 0.082* |
| n (%) | 21 (43.8) | 7 (14.6) | |
| PFIQ-7, mean (SD) | |||
| POPIQ-7 | 33.50 (26.6) | 8.40 (17.5) | <0.001* |
| UIQ-7 | 28.80 (28.5) | 10.40 (18.9) | <0.001* |
| CRAIQ-7 | 12.40 (21.2) | 2.00 (7.4) | 0.004* |
| P | 0.002† |
*Paired-sample t-test of the symptom scores before and after surgery; †Univariate one-way ANOVA of the difference between the improvements of POPIQ-7, UIQ-7 and CRAIQ-7. SD: Standard deviation; PGI-C: Patient global impression of change; PISQ: Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire; PFIQ: Pelvic Floor Impact Questionnaire; POPIQ: Pelvic organ Prolapse Impact Questionnaire; UIQ: Urinary Impact Questionnaire; CRAIQ: Colorectal-anal Impact Questionnaire; ANOVA: Analysis of variance.